IFGCURE

We build applications and content using extended reality (XR) simulation technology that can treat patients with mental health and/or substance use disorders. We hope to utilize emerging technologies to mitigate the impact of the current opioid crisis. By combining XR environments with exposure therapy and cue reactivity, IFGCure aims to extinguish negative conditioned responses relating to substance addiction and mental health, among others. Our goal is to aid licensed healthcare professionals in providing a superior avenue of treatment with our Software products.

Company

What does IFGCure do?
Exposure therapy
Exposure therapy is a type of behavior therapy used to treat anxiety and other disorders. It involves exposing a person to the feared object or situation in a safe environment in order to overcome his or her anxiety and/or distress. This can involve directly facing the feared object or situation, vividly imagining it, or experiencing it via XR technology.
VR as an alternative treatment
Many patients report being more comfortable with the VR treatment approach as an alternative to more traditional “talk therapy”. While VR has already been prevalent in phobia treatment, advances in technology are facilitating expanded use to mental health and addiction treatment. Med VR is also making vast developments in treating people with posttraumatic stress disorder (PTSD), particularly those who have felt combat trauma.
Accessible care
Med XR can combat the difficulty many people face in accessing qualified mental health professionals. Less than one third of adults with a diagnosable mental health disorder receive treatment in a given year. Med XR can combat this difficulty by making care more easily accessible.
Fills a need
Behavioral health disorders cost an estimated $467 billion per year in the U.S. in lost productivity and $2.5 trillion globally per year in medical expenses. The extreme shortage of mental health professionals available to treat this population and lack of patient access to care is placing a burden on qualified mental health practitioners and facilities. Early indicators point to Med XR as a viable solution to many of the challenges facing patients and practitioners in the behavioral health field.

Management

Dr. Stephen L., Chairman and CEO
Stephen brings more than 25 years of experience as an entrepreneur, academic orthopedic sports surgeon, and senior advisor to medical device companies and financial organizations across the U.S. and Asia. Stephen is both a General Partner and Venture Partner in BioVentures Investors Fund, IFG88 Fund, and Uptick Health Advisors, all of which are strategically focused on making investments in medical technology, pharmaceuticals, healthcare services and behavioral health. Stephen is currently co-GP of the Concerted Care Group, The Lodge, Medtek21 and sits on the board of directors for the Veterans Accountable Care Group (VACO) and POC Medical, a point-of-care portable device company focused on cancer detection.

Stephen was on the board of CardoMed (CDOM), later acquired by Arthrex, and its public shell was reversed into BioCardia (BRCA), a stem cell device company focusing on the treatment of heart failures. Stephen is a Senior Advisor to Opko Health (OPK) and Strategic Advisor to Ladenburg Thalmann (LTS). Stephen has served as a board member of American International Bank, as Founder/Chairman of Interbusiness Bank, and as Chairman of First China Capital Partners, all of which were acquired. Stephen was also a two-term Chairman of the National Association of Chinese-American Bankers Association.

In 2013, he was elected as a founding board member of the Yale Asia Development Council. He has served on the board of the Center Theater Group (CTG) and the World Affair Council in Los Angeles. He was also the recipient of the Verdugo Hospital Humanitarian Award in Southern California. Stephen has co-authored 7 books, published over 40 peer reviewed articles, and has lectured over 100 presentations in over 25 countries. He was a clinical advisor to Asia J&J, Stryker, and became the director of the bio-skill laboratory while he was an assistant professor at the UCLA School of Medicine. His team also commercialized several medical device R&D projects, which were later acquired. Stephen holds a B.A. in Biology and Psychology from UCLA, and an M.D. from the University of Southern California.
Seiji L., President, COO, Director
Alongside founding the IFGCure team, Seiji is a Partner on the IFG88 team focused on identifying, evaluating and executing public market, strategic and venture capital investments. Prior to this, Seiji worked in New York as a Private Equity Associate for Court Square Capital Partners (fka CVC Capital), a ~$6.5bn AUM private equity firm, focused on technology and telecom investments. Prior to that, Seiji worked for 2 years as an analyst in J.P. Morgan’s NY Healthcare investment banking group, where he focused on the pharma, medtech and healthcare IT/services sectors executing deals totaling over $27bn across mergers and acquisitions, structured transactions and debt and equity financings.

Outside of work, Seiji has been involved as an alumni interviewer for the Harvard College Admissions Committee and as a mentor with Apex for Youth.

Seiji graduated from Harvard University with an A.B. in Economics, with extensive coursework in global health policy, psychology and the life sciences. While at Harvard, Seiji was a 4-year member of the Varsity Golf team, Vice President of the Asian American Association, Kirkland House Chair for the Executive Committee of the Harvard College Fund, Director of Service for the AAB, and an active volunteer with the Cambridge School Volunteers program.
Bryan L., Vice President, Production and Operations
Prior to IFGCure, Bryan worked for a literary manager and producer at LBI Entertainment, an A-list management company in Los Angeles with clients such as Leonardo DiCaprio and Martin Scorsese. While there, Bryan was able to identify talented, emerging writers by combing through hundreds of scripts -- also learning how to package and sell material on top of handling a heavy volume of calls for his boss, coordinating with various industry execs and producers. He got his feet wet at ICM Partners, a full service talent agency in LA, starting in the mailroom before landing on a Motion Picture Literary agent’s desk. Outside of work, Bryan serves as an Alumni Interviewer for Harvard College and is an avid consumer of content.

Bryan graduated from Harvard University with an A.B. in Economics and a Secondary Degree in Psychology, with coursework in Behavioral Economics, Developmental and Social Psychology, and the relationship between Neuroscience, Philosophy, and Morality. He served as President of AAB and was an active volunteer in Chinatown ESL, teaching English classes to native Chinese speakers in the Boston area.

Board of Advisors

Thomas McLellan, Ph.D
Dr. Thomas McLellan is the premiere addiction expert in the United States, and the Founder and Chairman of the Board of Directors at the Treatment Research Institute, a not-for-profit research and development institute in Philadelphia. He served as the Deputy Director of the Office of National Drug Control Policy under the first Obama administration and is considered to be the top expert on the chronic addiction treatment model. In fact, it is Dr. McLellan’s 2000 article that is most often cited when anyone refers to addiction as a chronic condition. Dr. McLellan was the developer of the Addiction Severity Index (ASI), one of the most widely used substance abuse assessment instruments in the field. He has served as an adviser to many government and non-profit scientific organizations, including the Office of National Drug Control Policy, the National Practice Laboratory of the American Psychiatric Association, the Swiss National Science Foundation, the World Health Organization, the Greek government, and public health England.

Dr. McLellan, along with Drs. Kane, Whitefield, and Jaffe will help oversee the Et3 clinical trials, assuring that CCG’s approach is the most complete and effective in the nation. Additionally, Dr. McLellan will help produce a white paper on its groundbreaking program and will contribute to the publication of manuscripts and conference presentations related to outcomes from these ongoing assessments.
Skip Rizzo, Ph.D
Albert “Skip” Rizzo, Ph.D. is the Director of Medical Virtual Reality (MedVR) at the University of Southern California Institute for Creative Technologies and has Research Professor appointments with the USC Dept. of Psychiatry and Behavioral Sciences, and at the USC Davis School of Gerontology.

Dr. Rizzo conducts research on the design, development and evaluation of Virtual Reality (VR) systems targeting the areas of clinical assessment, treatment and rehabilitation. This work spans the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. In the psychological domain, the BRAVEMIND (Virtual Iraq/Afghanistan) project has focused on the creation of a VR exposure therapy application for combat-related PTSD with OIF/OEF service members and veterans. This system, now disseminated to over 100 sites, has also been retooled to address PTSD due to military sexual trauma and as a stress resilience/coping strategy training application for use prior to a combat deployment.

Dr. Rizzo has over 250 peer-reviewed publications and his work has been covered extensively via international media outlets. He is a Senior Editor of the MIT Press journal, Presence: Teleoperators and Virtual Environments, and has served on the editorial boards of numerous journals in the areas of media, healthcare, cognition, and computer/information technology (Cognitive Technology; Media Psychology, Cyberpsychology and Behavior, Journal of Computer Animation and Virtual Worlds; Computer Games Journal, Future Internet, Journal of Healthcare Communications) and is the creator/moderator of VRPSYCH listserve and Facebook page. He received the “American Psychological Association 2010 Award for Outstanding Contribution to the Practice of Trauma Psychology,” the MMVR Satava Award for excellence in the use of VR for therapeutic applications, the 2015 Society for Brain Mapping and Therapeutics “Pioneer in Medicine Award,” and recently was inducted into the National Academy of Inventors. Dr. Rizzo is also involved in the creation of artificially intelligent virtual human (VH) patients that novice clinicians can use to practice skills required for challenging diagnostic interviews. His cognitive work has addressed the use of VR applications to test and train attention, memory, visuospatial abilities and executive function across the lifespan. In his spare time, he plays rugby, listens to music, rides his motorcycle and thinks about new ways that VR can have a positive impact on clinical care and other pro-social purposes.
Jay Nussbaum
Mr. Nussbaum has extensive executive experience in government and commercial sales and management. He previously served as executive vice president of Oracle Service Industries under Oracle’s chairman and CEO, Larry Ellison, where he oversaw government, education, health, communications, utilities and financial services operations.

During his nearly 10-year career at Oracle, he helped grow the U.S. government business from less than $60 million to more than $1.5 billion. Under Nussbaum’s stewardship as founder, vice chairman and chief operating officer of Agilex Technologies Inc., the company grew to over $300 million in revenue and is now part of Accenture Federal Services, a provider of mission and technology solutions to the national security, healthcare and public sectors of the U.S. government.

He also served as global head of sales, marketing and business development for Citigroup Global Transaction Services, and as president of integrated systems operation at Xerox Corp. Nussbaum has also served on a number of boards of directors, including the Armed Forces Communications and Electronics Association, and Northrop Grumman Corp. He is active in numerous business and charitable organizations.

Board of Directors

Dr. Stephen L., Chairman and CEO
Stephen brings more than 25 years of experience as an entrepreneur, academic orthopedic sports surgeon, and senior advisor to medical device companies and financial organizations across the U.S. and Asia. Stephen is both a General Partner and Venture Partner in BioVentures Investors Fund, IFG88 Fund, and Uptick Health Advisors, all of which are strategically focused on making investments in medical technology, pharmaceuticals, healthcare services and behavioral health. Stephen is currently co-GP of the Concerted Care Group, The Lodge, Medtek21 and sits on the board of directors for the Veterans Accountable Care Group (VACO) and POC Medical, a point-of-care portable device company focused on cancer detection.

Stephen was on the board of CardoMed (CDOM), later acquired by Arthrex, and its public shell was reversed into BioCardia (BRCA), a stem cell device company focusing on the treatment of heart failures. Stephen is a Senior Advisor to Opko Health (OPK) and Strategic Advisor to Ladenburg Thalmann (LTS). Stephen has served as a board member of American International Bank, as Founder/Chairman of Interbusiness Bank, and as Chairman of First China Capital Partners, all of which were acquired. Stephen was also a two-term Chairman of the National Association of Chinese-American Bankers Association.

In 2013, he was elected as a founding board member of the Yale Asia Development Council. He has served on the board of the Center Theater Group (CTG) and the World Affair Council in Los Angeles. He was also the recipient of the Verdugo Hospital Humanitarian Award in Southern California. Stephen has co-authored 7 books, published over 40 peer reviewed articles, and has lectured over 100 presentations in over 25 countries. He was a clinical advisor to Asia J&J, Stryker, and became the director of the bio-skill laboratory while he was an assistant professor at the UCLA School of Medicine. His team also commercialized several medical device R&D projects, which were later acquired. Stephen holds a B.A. in Biology and Psychology from UCLA, and an M.D. from the University of Southern California.
Seiji L., President, COO, Director
Alongside founding the IFGCure team, Seiji is a Partner on the IFG88 team focused on identifying, evaluating and executing public market, strategic and venture capital investments. Prior to this, Seiji worked in New York as a Private Equity Associate for Court Square Capital Partners (fka CVC Capital), a ~$6.5bn AUM private equity firm, focused on technology and telecom investments. Prior to that, Seiji worked for 2 years as an analyst in J.P. Morgan’s NY Healthcare investment banking group, where he focused on the pharma, medtech and healthcare IT/services sectors executing deals totaling over $27bn across mergers and acquisitions, structured transactions and debt and equity financings.

Outside of work, Seiji has been involved as an alumni interviewer for the Harvard College Admissions Committee and as a mentor with Apex for Youth.

Seiji graduated from Harvard University with an A.B. in Economics, with extensive coursework in global health policy, psychology and the life sciences. While at Harvard, Seiji was a 4-year member of the Varsity Golf team, Vice President of the Asian American Association, Kirkland House Chair for the Executive Committee of the Harvard College Fund, Director of Service for the AAB, and an active volunteer with the Cambridge School Volunteers program.
Glen March, M.D.
Dr. Glen March is currently the Chairman and CEO of March Vision Care, Inc., a Knox-Keene licensed, national vision benefit company based in Los Angeles. He was director of Residency Training Program, Neuro-Ophthalmology Service, and Orbital and Ophthalmic Plastic Surgery Service at Charles R. Drew University of Medicine and Science. Dr. March was also an Assistant Professor of Ophthalmology and Neurosciences at Charles R. Drew University of Medicine and Science. He was an Assistant Professor of Ophthalmology at UCLA Jules Stein Eye Institute. He has received numerous awards and honors including Fellow of the Year from Massachusetts Eye and Ear Infirmary at Harvard Medical School, Service Leadership Award from L.A. County Intern and Residents, and Travel Fellowship from Association for Research in Vision and Ophthalmology (A.R.V.O.). He is a recognized expert in the medical and surgical management of neurologic vision loss. Dr. March also led a White House briefing on racial disparities and visual impairment during the Clinton Administration.

Dr. March earned his B.A. degree from Queens College in Flushing, N.Y., where he was a member of Beta Delta Chi honor society. He earned his medical degree while receiving a Deans Fellowship at University of Rochester in N.Y., and completed his residency in Ophthalmology at King/Drew Medical Center in L.A. He completed fellowships at Massachusetts Eye and Ear Infirmary, Harvard Medical School in Neuro-Ophthalmology, and at UCLA Jules Stein Eye Institute in Orbital and Ophthalmic Reconstructive Surgery. Dr. March is married and has 3 children. In addition to spending time with his children and their many activities, he enjoys basketball and martial arts. He has a passion for writing within the fields of Ophthalmology and Neurology and has published several articles and books on the topic.

Contact

Your message has been sent. Thank you!